Summary
General Electric Company (GE) announced the completion of the sale of its BioPharma business within its Healthcare segment to Danaher Corporation on March 31, 2020. The transaction generated total consideration of $21.1 billion, comprising $20.7 billion in cash and the assumption of $0.4 billion in pension liabilities by Danaher. This significant divestiture is a key step in GE's ongoing strategy to streamline its operations and improve its financial flexibility. The cash proceeds from this sale are expected to strengthen GE's balance sheet and provide resources for debt reduction or strategic reinvestment. Investors should note that the filing includes unaudited pro forma financial information as of December 31, 2019, and for the year ended December 31, 2019. This pro forma data reflects the financial impact of the BioPharma sale, offering a clearer view of GE's standalone business performance and financial position post-divestiture. The analysis of these pro forma statements will be crucial for understanding the company's operational trajectory and financial health moving forward.
Key Highlights
- 1Completion of the sale of GE's BioPharma business to Danaher Corporation on March 31, 2020.
- 2Total consideration received is $21.1 billion, consisting of $20.7 billion in cash and $0.4 billion in assumed pension liabilities.
- 3Cash proceeds of $20.3 billion received on March 31, 2020, with an additional $0.4 billion received on April 1, 2020.
- 4The sale represents a significant divestiture, aligning with GE's strategy to reduce debt and simplify its business portfolio.
- 5Unaudited pro forma financial statements reflecting the impact of the BioPharma sale are included as an exhibit.
- 6The pro forma financial statements provide a view of GE's financial position and earnings as if the sale had occurred earlier.